ADAR1 Capital Management, LLC
AUSTIN, TX · CIK 1940272 · 13F filing filed 2026-08-14
SEC-registered investment adviser since 2024 · limited liability company
- Assets managed$1.7bn
- Staff11 · 7 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds2 (2 hedge) · $1.3bn gross assets
- Form ADV · 2026-03-31SEC adviser record
- Legal entityADAR1 CAPITAL MANAGEMENT, LLC (US)
Options: 6 call positions ($8.8m notional), 4 put positions ($48.8m notional) – listed below, not included above.
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| ABIVAX SA ABVX | $240.5m11.30% | Added +410.7k |
| PROTAGONIST THERAPEUTICS INC PTGX | $117.8m5.54% | Reduced -33.3k |
| ROIVANT SCIENCES LTD ROIV | $111.7m5.25% | Reduced -128.9k |
| SPDR S&P 500 ETF TR SPY | $96.4m4.53% | Added +53.1k |
| IMMUNOVANT INC IMVT | $89.8m4.22% | Reduced -348.3k |
| ZAI LAB LTD ZLAB | $64.0m3.01% | Added +1.9m |
| AGIOS PHARMACEUTICALS INC AGIO | $47.8m2.25% | Added +1.1m |
| CRINETICS PHARMACEUTICALS IN CRNX | $45.7m2.15% | Added +82.7k |
| EA SERIES TRUST BOXX | $39.5m1.86% | Unchanged |
| CYTOKINETICS INC CYTK | $39.0m1.83% | Reduced -174.6k |
| SEPTERNA INC SEPN | $31.5m1.48% | Reduced -149.1k |
| ANTERIS TECHNOLOGIES GLOBAL AVR | $31.0m1.46% | Reduced -644.0k |
| EDITAS MEDICINE INC EDIT | $28.8m1.35% | New |
| DENALI THERAPEUTICS INC DNLI | $26.5m1.24% | Reduced -842.4k |
| SPYRE THERAPEUTICS INC SYRE | $25.2m1.19% | Reduced -54.3k |
| VIR BIOTECHNOLOGY INC VIR | $25.0m1.18% | Reduced -288.0k |
| PRAXIS PRECISION MEDICINES I PRAX | $24.9m1.17% | Added +72.8k |
| INSMED INC INSM | $24.4m1.15% | Added +193.1k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $23.1m1.08% | Added +191.7k |
| VIKING THERAPEUTICS INC VKTX | $22.4m1.05% | Added +346.3k |
| TAYSHA GENE THERAPIES INC TSHA | $20.7m0.97% | Added +61.0k |
| MONOPAR THERAPEUTICS INC MNPR | $20.1m0.95% | Reduced -46.7k |
| OVID THERAPEUTICS INC OVID | $20.0m0.94% | Added +2.9m |
| ENLIVEN THERAPEUTICS INC ELVN | $19.7m0.92% | Added +58.2k |
| ENANTA PHARMACEUTICALS INC ENTA | $19.6m0.92% | Added +1.3m |
| NEKTAR THERAPEUTICS NKTR | $17.0m0.80% | Added +82.9k |
| INSPIRE MED SYS INC INSP | $16.7m0.79% | Reduced -30.6k |
| REVOLUTION MEDICINES INC RVMD | $16.4m0.77% | Reduced -46.4k |
| ESTABLISHMENT LABS HLDGS INC ESTA | $15.9m0.75% | Reduced -27.9k |
| PROTHENA CORP PLC PRTA | $15.2m0.72% | Reduced -26.9k |
| RHYTHM PHARMACEUTICALS INC RYTM | $15.1m0.71% | Reduced -75.3k |
| INHIBIKASE THERAPEUTICS INC IKT | $15.0m0.70% | Added +780.6k |
| UNIQURE NV QURE | $15.0m0.70% | Added +248.5k |
| RALLYBIO CORP RLYB | $14.8m0.70% | Added +905.8k |
| REGENERON PHARMACEUTICALS REGN | $13.8m0.65% | Added +10.1k |
| INVENTIVA SA IVA | $13.6m0.64% | Added +1.4m |
| SUTRO BIOPHARMA INC STRO | $13.4m0.63% | Reduced -120.4k |
| IONIS PHARMACEUTICALS INC IONS | $13.2m0.62% | Added +5.9k |
| BRIDGEBIO PHARMA INC BBIO | $13.2m0.62% | Added +82.4k |
| SAREPTA THERAPEUTICS INC SRPT | $13.1m0.62% | Added +468.6k |
| CYTOMX THERAPEUTICS INC CTMX | $12.6m0.59% | Reduced -45.1k |
| VOR BIOPHARMA INC VOR | $12.5m0.59% | New |
| SPDR SER TR BIL | $12.4m0.58% | Unchanged |
| EQUILLIUM INC EQ | $12.0m0.57% | Added +31.9k |
| ADLAI NORTYE LTD ANL | $11.7m0.55% | Added +899.9k |
| CLIMB BIO INC CLYM | $10.7m0.50% | Added +225.0k |
| HELIX ACQUISITION CORP III HLXC | $10.6m0.50% | Unchanged |
| ZURA BIO LTD ZURA | $10.4m0.49% | Added +1.1m |
| ONKURE THERAPEUTICS INC OKUR | $10.2m0.48% | Reduced -196.3k |
| MAZE THERAPEUTICS INC MAZE | $10.1m0.48% | Added +289.2k |
| XENON PHARMACEUTICALS INC XENE | $10.1m0.47% | Reduced -62.3k |
| TEVA PHARMACEUTICAL INDS LTD SPONSORED ADS | $9.4m0.44% | Added +9.5k |
| UROGEN PHARMA LTD URGN | $9.3m0.44% | Reduced -143.1k |
| FAETH THERAPEUTICS INC FTH | $9.0m0.42% | New |
| AMYLYX PHARMACEUTICALS INC AMLX | $8.9m0.42% | Reduced -506.2k |
| DBV TECHNOLOGIES S A DBVT | $8.7m0.41% | Reduced -484.6k |
| SAVARA INC SVRA | $8.6m0.41% | Reduced -61.1k |
| VAXCYTE INC PCVX | $8.5m0.40% | Reduced -113.1k |
| CG ONCOLOGY INC CGON | $8.4m0.40% | Reduced -67.0k |
| MINERALYS THERAPEUTICS INC MLYS | $8.1m0.38% | Added +144.2k |
| ASCENDIS PHARMA A/S ASND | $7.6m0.36% | New |
| AMANAT ACQUISITION CORP AMAN | $7.6m0.36% | New |
| NURIX THERAPEUTICS INC NRIX | $7.6m0.36% | Added +257.2k |
| BIOHAVEN LTD BHVN | $7.5m0.35% | Added +456.9k |
| PRIME MEDICINE INC PRME | $7.4m0.35% | Added +24.3k |
| PERCEPTIVE CAP SOLUTIONS COR FRNM | $7.3m0.35% | Added +175.1k |
| OPUS GENETICS INC IRD | $7.3m0.34% | Reduced -65.2k |
| LEXEO THERAPEUTICS INC LXEO | $7.3m0.34% | Added +98.6k |
| DAMORA THERAPEUTICS INC COM NEW | $7.3m0.34% | Added +1.0k |
| REPLIMUNE GROUP INC REPL | $7.3m0.34% | Reduced -927.2k |
| LEONABIO INC LONA | $7.1m0.34% | Added +49.6k |
| KORRO BIO INC KRRO | $7.1m0.33% | Unchanged |
| RESEARCH ALLIANCE CORP III RACC | $7.0m0.33% | New |
| INFLARX NV IFRX | $6.7m0.32% | Added +2.8m |
| RELAY THERAPEUTICS INC RLAY | $6.7m0.32% | New |
| JANUX THERAPEUTICS INC JANX | $6.5m0.30% | Added +122.3k |
| PLIANT THERAPEUTICS INC PLRX | $6.3m0.30% | Added +2.9m |
| AADI BIOSCIENCE INC WHWK | $6.1m0.29% | Added +1.2m |
| KRYSTAL BIOTECH INC KRYS | $6.1m0.29% | Reduced -3.6k |
| ARBUTUS BIOPHARMA CORP ABUS | $6.1m0.29% | Reduced -1.9m |
| PFIZER INC PFE | $6.1m0.29% | Added +175.0k |
| BRIGHTHOUSE FINL INC BHF | $6.0m0.28% | Unchanged |
| EDGEWISE THERAPEUTICS INC EWTX | $5.8m0.27% | Added +52.6k |
| ALECTOR INC ALEC | $5.8m0.27% | Added +1.8m |
| FULCRUM THERAPEUTICS INC FULC | $5.7m0.27% | Added +1.4m |
| ARROWHEAD PHARMACEUTICALS IN ARWR | $5.7m0.27% | Reduced -500 |
| ACUMEN PHARMACEUTICALS INC ABOS | $5.6m0.26% | Reduced -45.0k |
| OAKTREE ACQUISITION CORP III OACCU | $5.6m0.26% | Unchanged |
| GLOBUS MED INC GMED | $5.5m0.26% | Added +50.0k |
| MONTE ROSA THERAPEUTICS INC GLUE | $5.2m0.25% | Added +1.0k |
| DISCIPLINED GROWTH DGAC.U | $5.0m0.24% | New |
| BHAV ACQUISITION CORP BHAVU | $5.0m0.24% | Unchanged |
| BRIDGEBIO PHARMA INC BBIO 1.75 03.01.31 · principal | $5.0m0.23% | Unchanged |
| BRIDGEBIO PHARMA INC BBIO 2.25 02.01.29 · principal | $4.9m0.23% | Unchanged |
| DANAHER CORPORATION DHR | $4.9m0.23% | Reduced -5.0k |
| BOUNDLESS BIO INC BOLD | $4.9m0.23% | New |
| AVALYN PHARMACEUTICALS INC AVLN | $4.8m0.23% | New |
| ARS PHARMACEUTICALS INC SPRY | $4.8m0.23% | Reduced -760.5k |
| ATAIBECKLEY INC ATAI | $4.8m0.23% | Unchanged |
| PRELUDE THERAPEUTICS INC PRLD | $4.8m0.23% | Added +748.1k |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| TERNS PHARMACEUTICALS INC | $48.2m914.7k shares |
| BEAM THERAPEUTICS INC BEAM | $34.5m1.4m shares |
| SCHOLAR ROCK HLDG CORP SRRK | $20.0m407.3k shares |
| VERTEX PHARMACEUTICALS INC VRTX | $6.7m15.1k shares |
| VIRIDIAN THERAPEUTICS INC VRDN | $6.0m304.4k shares |
| ASCENDIS PHARMA A/S | $5.7m25.0k shares |
| ELI LILLY & CO LLY | $4.7m5.1k shares |
| DIANTHUS THERAPEUTICS INC DNTH | $4.6m55.0k shares |
| BELITE BIO INC BLTE | $4.3m26.9k shares |
| ARCELLX INC ACLX | $3.7m32.1k shares |
| ARRIVENT BIOPHARMA INC AVBP | $3.3m141.8k shares |
| APELLIS PHARMACEUTICALS INC APLS | $2.9m72.5k shares |
| MASIMO CORP MASI | $2.7m15.0k shares |
| TELEFLEX INCORPORATED TFX | $2.5m21.2k shares |
| BIOAGE LABS INC BIOA | $2.4m135.6k shares |
| ALKERMES PLC ALKS | $1.6m46.4k shares |
| SOLENO THERAPEUTICS INC SLNO | $1.6m46.8k shares |
| CENTESSA PHARMACEUTICALS PLC | $1.5m38.6k shares |
| AMICUS THERAPEUTICS INC FOLD | $1.5m105.0k shares |
| UNITEDHEALTH GROUP INC UNH | $1.5m5.5k shares |
| SENSIENT TECHNOLOGIES CORP SXT | $1.3m15.0k shares |
| SCHRODINGER INC SDGR | $1.2m101.5k shares |
| 4D MOLECULAR THERAPEUTICS IN FDMT | $1.1m116.7k shares |
| DAY ONE BIOPHARMACEUTICALS I | $1.1m49.9k shares |
| BRISTOL-MYERS SQUIBB CO BMY | $1.1m17.5k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| ISHARES TR IWM · Put | $18.8m62.5k shares | Added |
| SPDR S&P 500 ETF TR SPY · Put | $18.7m25.0k shares | New |
| SPDR SER TR XBI · Put | $10.7m67.4k shares | Added |
| ABIVAX SA ABVX · Call | $5.9m44.4k shares | Added |
| KEEN VISION ACQUISITION CORP KVACF · Call | $930.0k75.0k shares | Unchanged |
| AMYLYX PHARMACEUTICALS INC AMLX · Put | $720.2k40.1k shares | New |
| ULTRAGENYX PHARMACEUTICAL IN RARE · Call | $667.8k20.0k shares | Unchanged |
| NOVO-NORDISK A S NVO · Call | $623.2k13.0k shares | Unchanged |
| CORBUS PHARMACEUTICALS HLDGS CRBP · Call | $562.8k60.0k shares | Added |
| SOLIDION TECHNOLOGY INC STI · Call | $125.4k13.5k shares | Unchanged |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| RALLYBIO CORP RLYB · 13G · filed 2026-06-05 | 17.5%≈ $14.8m |
| INMED PHARMACEUTICALS INC INM · 13G · filed 2026-10-07 | 17.2%≈ $971.9k |
| NEXTCURE INC NXTC · 13G · filed 2026-08-14 | 15.8%≈ $1.2m |
| TENAX THERAPEUTICS INC TENX · 13G · filed 2026-09-08 | 14.0%≈ $76.5m |
| GRACE THERAPEUTICS INC GRCE · 13G · filed 2026-08-14 | 9.9%≈ $4.0m |
| KIORA PHARMACEUTICALS INC KPRX · 13G · filed 2026-08-14 | 9.9%≈ $1.3m |
| INHIBIKASE THERAPEUTICS INC IKT · 13G · filed 2026-05-15 | 9.9%≈ $28.1m |
| EQUILLIUM INC EQ · 13G · filed 2026-05-15 | 9.9%≈ $21.1m |
| ACASTI PHARMA INC 13G · filed 2025-11-14 | 9.9% |
| AMANAT ACQUISITION CORP AMAN · 13G · filed 2026-08-14 | 9.6%≈ $7.6m |
| PLIANT THERAPEUTICS INC PLRX · 13G · filed 2026-08-14 | 8.9%≈ $6.3m |
| BOUNDLESS BIO INC BOLD · 13G · filed 2026-08-14 | 8.8%≈ $4.9m |
| RESEARCH ALLIANCE CORP III RACC · 13G · filed 2026-08-14 | 8.4%≈ $7.0m |
| LEONABIO INC LONA · 13G · filed 2026-05-15 | 7.7%≈ $6.7m |
| CYCLERION THERAPEUTICS INC 13G · filed 2026-08-14 | 7.0%≈ $1.0m |
| EDITAS MEDICINE INC EDIT · 13G · filed 2026-08-14 | 5.8%≈ $28.8m |
| HELIX ACQUISITION CORP III HLXC · 13G · filed 2026-05-15 | 5.6%≈ $10.6m |
| ADAGIO MED HLDGS INC ADGM · 13G · filed 2026-08-14 | 5.4%≈ $785.5k |
| JATT II ACQUISITION CORP JATT · 13G · filed 2026-08-14 | 5.4%≈ $4.7m |
| REIN THERAPEUTICS INC RNTX · 13G · filed 2026-08-14 | 5.3%≈ $4.7m |
Trades reported as a company insider since 1 Apr 2026
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2026-09-16 | INMED PHARMACEUTICALS INC 10% owner · See Footnote | Bought | $10.8k8.3k shares |
| 2026-09-15 | INMED PHARMACEUTICALS INC 10% owner · See Footnote | Bought | $70.5k54.3k shares |
| 2026-09-14 | INMED PHARMACEUTICALS INC 10% owner · See Footnote | Bought | $36.8k28.5k shares |
| 2026-09-03 | TENAX THERAPEUTICS INC 10% owner · See Footnote | Bought | —900.0k shares |
| 2026-09-02 | TENAX THERAPEUTICS INC 10% owner · See Footnote | Bought | —187.7k shares |
| 2026-09-01 | TENAX THERAPEUTICS INC 10% owner · See Footnote | Bought | —179.1k shares |
| 2026-08-31 | TENAX THERAPEUTICS INC 10% owner · See Footnote | Bought | —403.6k shares |
| 2026-08-24 | TENAX THERAPEUTICS INC 10% owner · See Footnote | Bought | —107.4k shares |
| 2026-08-21 | TENAX THERAPEUTICS INC 10% owner · See Footnote | Bought | —716.4k shares |
| 2026-08-20 | TENAX THERAPEUTICS INC 10% owner · See Footnote | Bought | —202.1k shares |
| 2026-07-31 | NEXTCURE INC 10% owner · See Footnote | Bought | $179.3k36.3k shares |
| 2026-07-30 | NEXTCURE INC 10% owner · See Footnote | Bought | $1.4m292.9k shares |
| 2026-07-29 | NEXTCURE INC 10% owner · See Footnote | Bought | $17.1k3.4k shares |
| 2026-07-28 | NEXTCURE INC 10% owner · See Footnote | Bought | $31.7k6.4k shares |
| 2026-07-27 | NEXTCURE INC 10% owner · See Footnote | Bought | $39.0k7.8k shares |
| 2026-07-15 | INMED PHARMACEUTICALS INC 10% owner · See Footnote | Bought | $1.6k1.0k shares |
| 2026-05-19 | INMED PHARMACEUTICALS INC 10% owner · See Footnote | Bought | $721.7k468.6k shares |
| 2026-05-19 | RALLYBIO CORP 10% owner · See Footnote | Bought | $142.6k10.2k shares |
| 2026-05-18 | RALLYBIO CORP 10% owner · See Footnote | Bought | $84.0k6.0k shares |
| 2026-05-15 | RALLYBIO CORP 10% owner · See Footnote | Bought | $4.2k300 shares |
| 2026-05-13 | RALLYBIO CORP 10% owner · See Footnote | Bought | $1.1m79.3k shares |
| 2026-05-12 | RALLYBIO CORP 10% owner · See Footnote | Bought | $11.1k800 shares |
| 2026-05-11 | RALLYBIO CORP 10% owner · See Footnote | Bought | $700.0k50.0k shares |
| 2026-05-05 | RALLYBIO CORP 10% owner · See Footnote | Bought | $491.4k35.1k shares |
| 2026-05-04 | RALLYBIO CORP 10% owner · See Footnote | Bought | $1.7m120.8k shares |